MorphoSys Announces Clinical Milestone in Ophthalmology Program

MorphoSys Announces Clinical Milestone in Ophthalmology Program 
MARTINSRIED, GERMANY and MUNICH, GERMANY -- (Marketwired) -- 05/02/13
--  MorphoSys AG / MorphoSys Announces Clinical Milestone in
Ophthalmology Program . Processed and transmitted by Thomson Reuters
ONE. The issuer is solely responsible for the content of this
announcement. 
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced
today that it has received a milestone payment from Novartis in
connection with the clinical
trial application (CTA/IND) and
projected initiation of a Phase 1 clinical trial. The HuCAL-derived,
fully human antibody will be developed in the therapeutic area of
ophthalmology. 
"Our pipeline of therapeutic antibody candidates is more advanced
than ever.
Today's news marks the first of up to five clinical
milestones from our collaborators that we expect to see during the
course of the year," commented
Dr. Marlies Sproll, Chief Scientific
Officer of MorphoSys AG. "In total, our
collaboration with Novartis
has resulted in seven clinical programs to date,
three currently
being in Phase 1 and four in Phase 2." 
Current Status of MorphoSys's Pipeline: 
In total, MorphoSys's pipeline now comprises 21 clinical programs. Of
these, 17 are partnered programs, of which nine are in Phase 1, seven
are in Phase 2 and
one is in Phase 2/3 development. The remaining
four are the Company's proprietary programs MOR103, which has
concluded a Phase 1b/2a trial for rheumatoid arthritis and is
currently being evaluated in a Phase 1b trial in
multiple sclerosis;
MOR208, which has concluded a Phase 1 trial for chronic lymphocytic
leukemia and will be evaluated in Phase 2 trials in B-ALL and
NHL;
and MOR202, which is in a Phase 1/2a trial for multiple myeloma. 
About MorphoSys: 
MorphoSys developed HuCAL, the most successful antibody library
technology in
the pharmaceutical industry. By successfully applying
this and other patented
technologies, MorphoSys has become a leader
in the field of therapeutic antibodies, one of the fastest-growing
drug classes in human healthcare. Together with its pharmaceutical
partners, MorphoSys has built a therapeutic
pipeline of more than 70
human antibody drug candidates for the treatment of
cancer,
rheumatoid arthritis, and Alzheimer's disease, to 
name just a few.
With
its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under
the symbol MOR. For regular updates
about MorphoSys, visit
http://www.morphosys.com 
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R) and Ylanthia(R) and 100 billion high potentials(R) are
registered trademarks of MorphoSys AG. 
Slonomics(R) is a registered trademark of Sloning BioTechnology GmbH,
a subsidiary
of MorphoSys AG. 
This communication contains certain forward-looking statements
concerning the
MorphoSys group of companies. The forward-looking
statements contained herein
represent the judgment of MorphoSys as of
the date of this release and involve
risks and uncertainties. Should
actual conditions differ from the Company's assumptions, actual
results and actions may differ from those anticipated. MorphoSys does
not intend to update any of these forward-looking statements as
far
as the wording of the relevant press release is concerned. 
Media Release (PDF): http://hugin.info/130295/R/1697992/559749.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: MorphoSys AG via Thomson Reuters ONE 
[HUG#1697992] 
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122 
Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454 
Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332 
investors@morphosys.com
 
 
Press spacebar to pause and continue. Press esc to stop.